354 related articles for article (PubMed ID: 29718973)
41. Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor.
Isfort S; Crysandt M; Gezer D; Koschmieder S; Brümmendorf TH; Wolf D
Recent Results Cancer Res; 2018; 212():87-108. PubMed ID: 30069626
[TBL] [Abstract][Full Text] [Related]
42. Novel Mechanisms for the Antifibrotic Action of Nintedanib.
Rangarajan S; Kurundkar A; Kurundkar D; Bernard K; Sanders YY; Ding Q; Antony VB; Zhang J; Zmijewski J; Thannickal VJ
Am J Respir Cell Mol Biol; 2016 Jan; 54(1):51-9. PubMed ID: 26072676
[TBL] [Abstract][Full Text] [Related]
43. Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Hill BG; Kota VK; Khoury HJ
Expert Rev Anticancer Ther; 2014 Jul; 14(7):765-70. PubMed ID: 24875651
[TBL] [Abstract][Full Text] [Related]
44. The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases.
Ozanne J; Prescott AR; Clark K
Biochem J; 2015 Jan; 465(2):271-9. PubMed ID: 25351958
[TBL] [Abstract][Full Text] [Related]
45. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
Puttini M; Coluccia AM; Boschelli F; Cleris L; Marchesi E; Donella-Deana A; Ahmed S; Redaelli S; Piazza R; Magistroni V; Andreoni F; Scapozza L; Formelli F; Gambacorti-Passerini C
Cancer Res; 2006 Dec; 66(23):11314-22. PubMed ID: 17114238
[TBL] [Abstract][Full Text] [Related]
46. Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts.
Cipriani P; Di Benedetto P; Ruscitti P; Verzella D; Fischietti M; Zazzeroni F; Liakouli V; Carubbi F; Berardicurti O; Alesse E; Giacomelli R
Arthritis Res Ther; 2015 Sep; 17(1):247. PubMed ID: 26357964
[TBL] [Abstract][Full Text] [Related]
47. Therapeutic targeting of SRC kinase in myofibroblast differentiation and pulmonary fibrosis.
Hu M; Che P; Han X; Cai GQ; Liu G; Antony V; Luckhardt T; Siegal GP; Zhou Y; Liu RM; Desai LP; O'Reilly PJ; Thannickal VJ; Ding Q
J Pharmacol Exp Ther; 2014 Oct; 351(1):87-95. PubMed ID: 25047515
[TBL] [Abstract][Full Text] [Related]
48. A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate.
Bhattacharyya S; Ishida W; Wu M; Wilkes M; Mori Y; Hinchcliff M; Leof E; Varga J
Oncogene; 2009 Mar; 28(10):1285-97. PubMed ID: 19151753
[TBL] [Abstract][Full Text] [Related]
49. Neutrophil FcγRIIA promotes IgG-mediated glomerular neutrophil capture via Abl/Src kinases.
Nishi H; Furuhashi K; Cullere X; Saggu G; Miller MJ; Chen Y; Rosetti F; Hamilton SL; Yang L; Pittman SP; Liao J; Herter JM; Berry JC; DeAngelo DJ; Zhu C; Tsokos GC; Mayadas TN
J Clin Invest; 2017 Oct; 127(10):3810-3826. PubMed ID: 28891817
[TBL] [Abstract][Full Text] [Related]
50. Bosutinib Acts as a Tumor Inhibitor via Downregulating Src/NF-κB/Survivin Expression in HeLa Cells.
Yu L; Guo W; Liu L; Zhang G; Zhang F; Qu Y; Liu Y; Li H; Li H
Anat Rec (Hoboken); 2019 Dec; 302(12):2193-2200. PubMed ID: 31569304
[TBL] [Abstract][Full Text] [Related]
51. Attenuation of fibrosis with selective inhibition of c-Abl by siRNA in systemic sclerosis dermal fibroblasts.
Karimizadeh E; Motamed N; Mahmoudi M; Jafarinejad-Farsangi S; Jamshidi A; Faridani H; Gharibdoost F
Arch Dermatol Res; 2015 Mar; 307(2):135-42. PubMed ID: 25527259
[TBL] [Abstract][Full Text] [Related]
52. The expression dynamics of transforming growth factor-β/Smad signaling in the liver fibrosis experimentally caused by Clonorchis sinensis.
Yan C; Wang L; Li B; Zhang BB; Zhang B; Wang YH; Li XY; Chen JX; Tang RX; Zheng KY
Parasit Vectors; 2015 Feb; 8():70. PubMed ID: 25649869
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis.
Avouac J; Palumbo K; Tomcik M; Zerr P; Dees C; Horn A; Maurer B; Akhmetshina A; Beyer C; Sadowski A; Schneider H; Shiozawa S; Distler O; Schett G; Allanore Y; Distler JH
Arthritis Rheum; 2012 May; 64(5):1642-52. PubMed ID: 22139817
[TBL] [Abstract][Full Text] [Related]
54. Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors.
Maurer B; Distler A; Dees C; Khan K; Denton CP; Abraham D; Gay RE; Michel BA; Gay S; Hw Distler J; Distler O
Ann Rheum Dis; 2013 Dec; 72(12):2039-46. PubMed ID: 24013728
[TBL] [Abstract][Full Text] [Related]
55. The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.
Avouac J; Palumbo-Zerr K; Ruzehaji N; Tomcik M; Zerr P; Dees C; Distler A; Beyer C; Schneider H; Distler O; Schett G; Allanore Y; Distler JH
Arthritis Rheumatol; 2014 Nov; 66(11):3140-50. PubMed ID: 25155144
[TBL] [Abstract][Full Text] [Related]
56. Bosutinib: a novel second-generation tyrosine kinase inhibitor.
Isfort S; Keller-v Amsberg G; Schafhausen P; Koschmieder S; Brümmendorf TH
Recent Results Cancer Res; 2014; 201():81-97. PubMed ID: 24756786
[TBL] [Abstract][Full Text] [Related]
57. Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects.
Hsyu PH; Pignataro DS; Matschke K
Eur J Clin Pharmacol; 2017 Jan; 73(1):57-63. PubMed ID: 27717999
[TBL] [Abstract][Full Text] [Related]
58. SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer.
Kim WG; Guigon CJ; Fozzatti L; Park JW; Lu C; Willingham MC; Cheng SY
Clin Cancer Res; 2012 Mar; 18(5):1281-90. PubMed ID: 22271876
[TBL] [Abstract][Full Text] [Related]
59. Human xylosyltransferase-I - a new marker for myofibroblast differentiation in skin fibrosis.
Faust I; Roch C; Kuhn J; Prante C; Knabbe C; Hendig D
Biochem Biophys Res Commun; 2013 Jul; 436(3):449-54. PubMed ID: 23747722
[TBL] [Abstract][Full Text] [Related]
60. The Src kinases Hck, Fgr and Lyn activate Arg to facilitate IgG-mediated phagocytosis and Leishmania infection.
Wetzel DM; Rhodes EL; Li S; McMahon-Pratt D; Koleske AJ
J Cell Sci; 2016 Aug; 129(16):3130-43. PubMed ID: 27358479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
